One of science’s great puzzles is being solved by artificial intelligence and the answers shared freely on the internet. How can life sciences companies make the most of DeepMind’s discoveries while protecting their own?
AI drug discovery
Startup HiberCell has acquired Genuity Science, a marriage that brings together two companies that apply AI and machine learning to drug research. HiberCell says Genuity will help the company identify and validate new pathways in how cancer starts and progresses.
Softbank led the Series C round of funding for Deep Genomics, a startup that applies its artificial intelligence technology to all aspects of discovering and developing new drugs. The Deep Genomics platform has yielded 10 programs; CEO Brendan Frey aims to advance four of them to the clinic in two years, all while tripling the …
Engine Biosciences closed a $43 million Series A financing that the startup will apply to its artificial intelligence-based technology for drug discovery. The company analyzes genetic interactions, “deciphering biology” to find new cancer drugs.
Leveraging artificial intelligence can shave years off the difficult process of diagnosing a rare disease. By safely sharing patient data, more will benefit globally.
In this article, experts forecast upcoming AI developments that will help shape a new commercial model, making 2021 the year when AI shifts from early exploration to broad adoption.
Ultimately, we should be excited about AI and its adoption in biopharma, but we should also stay sensible and focus our efforts where they’ll have the greatest impact.
The deal with Roche subsidiary Genentech is likely not the last for Genesis Therapeutics, which is based on AI research undertaken at Stanford. Such partnerships are potentially lucrative for drug-discovery startups.